CD86 and prostate cancer: Herein, the transcriptome levels of PD-L1 (CD274), CD86 and CD206 (MRCI) were found to be lower in many tumor tissues than in adjacent normal tissues, such as bladder urothelial carcinoma (BLCA), breast cancer (BRCA), colon cancer (COAD), hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), and prostate cancer (PRAD).